William Blair Reaffirms “Market Perform” Rating for Eyenovia (NASDAQ:EYEN)

William Blair reiterated their market perform rating on shares of Eyenovia (NASDAQ:EYEN) in a report released on Friday morning,Benzinga reports. William Blair also issued estimates for Eyenovia’s Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.47) EPS, Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.37) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Eyenovia in a report on Wednesday, November 13th.

Eyenovia Price Performance

EYEN stock opened at $0.11 on Friday. The company has a market capitalization of $7.11 million, a P/E ratio of -0.15 and a beta of 1.75. Eyenovia has a twelve month low of $0.09 and a twelve month high of $2.57. The business has a 50 day simple moving average of $0.48 and a 200-day simple moving average of $0.70. The company has a current ratio of 0.74, a quick ratio of 0.27 and a debt-to-equity ratio of 0.58.

Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same period in the prior year, the company earned ($0.18) earnings per share. As a group, equities analysts anticipate that Eyenovia will post -0.5 EPS for the current year.

Insider Buying and Selling

In other Eyenovia news, CEO Michael M. Rowe bought 50,000 shares of Eyenovia stock in a transaction on Monday, August 26th. The stock was bought at an average price of $0.57 per share, with a total value of $28,500.00. Following the completion of the acquisition, the chief executive officer now owns 82,927 shares in the company, valued at $47,268.39. The trade was a 151.85 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 7.10% of the company’s stock.

Institutional Investors Weigh In On Eyenovia

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Nations Financial Group Inc. IA ADV lifted its holdings in Eyenovia by 24.4% in the second quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock valued at $30,000 after acquiring an additional 10,000 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Eyenovia in the second quarter valued at $26,000. Ground Swell Capital LLC acquired a new stake in Eyenovia in the second quarter valued at $27,000. Financial Management Network Inc. acquired a new stake in Eyenovia in the third quarter valued at $39,000. Finally, SkyView Investment Advisors LLC acquired a new stake in Eyenovia in the second quarter valued at $87,000. Institutional investors and hedge funds own 25.84% of the company’s stock.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.